Cover Image
Market Research Report

Global Drug Safety Solutions and Pharmacovigilance Market: Industry Trends and Forecast to 2026

Published by Data Bridge Market Research Private Limited Product code 915549
Published Content info 455 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Drug Safety Solutions and Pharmacovigilance Market: Industry Trends and Forecast to 2026
Published: October 1, 2019 Content info: 455 Pages
Description

Global drug safety solutions and pharmacovigilance market is projected to register a substantial CAGR of 7.4% in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation:

By Type (Software, Services), End Users (Biotechnology & Pharmaceuticals, Contract Research Organizations (CROS), Hospitals, KPOs/BPOs, Healthcare Providers), Distribution Channel (Direct Sales, Retail Sales), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Some of the major factors contributing to the growth of the market are:

  • Increasing health care expenditure
  • Increasing number of pipeline products for treatment of various diseases

Market Players:

The key market players for global drug safety solutions and pharmacovigilance market are listed below:

  • Pharmaceutical Product Development, LLC
  • Drug Safety Solutions Limited
  • C3i
  • Worldwide Clinical Trials
  • Bioclinica
  • United Biosource LLC
  • Ennov
  • AB Cube
  • Covance Inc.
  • Accenture
  • PRA Health Sciences, Inc.
  • Ergomed
  • IQVIA
  • Genpact
  • Cognizant
  • Parexel International Corporation
  • ArisGlobal
  • ICON plc
  • Oracle
  • Syneos Health
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.8 DBMR MARKET POSITION GRID
  • 2.9 VENDOR SHARE ANALYSIS
  • 2.10 SECONDARY SOURCES
  • 2.11 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING NUMBER OF CLINICAL TRIALS
    • 3.1.2 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS
    • 3.1.3 INCREASE IN R & D EXPENDITURE BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
    • 3.1.4 INCREASE IN THE NUMBER OF ADVERSE DRUG REACTIONS (ADRS)
  • 3.2 RESTRAINT
    • 3.2.1 HIGH COST OF DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE
  • 3.3 OPPORTUNITIES
    • 3.3.1 AUTOMATION IN DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE
    • 3.3.2 RESEARCH COLLABORATIONS AND PARTNERSHIPS
    • 3.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
  • 3.4 CHALLENGE
    • 3.4.1 THE MISREPORTING AND MISCODING OF ADVERSE EVENTS

4 EXECUTIVE SUMMARY

5 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY TYPE

  • 5.1 OVERVIEW
  • 5.2 SOFTWARE
    • 5.2.1 ADVERSE EVENT REPORTING SOFTWARE
      • 5.2.1.1 ON-PREMISE
      • 5.2.1.2 CLOUD BASED
    • 5.2.2 DRUG SAFETY AUDITS SOFTWARE
      • 5.2.2.1 ON-PREMISE
      • 5.2.2.2 CLOUD BASED
    • 5.2.3 DATA MANAGEMENT SOFTWARE
      • 5.2.3.1 ON-PREMISE
      • 5.2.3.2 CLOUD BASED
    • 5.2.4 FULLY INTEGRATED SOFTWARE
      • 5.2.4.1 ON-PREMISE
      • 5.2.4.2 CLOUD BASED
    • 5.2.5 ISSUE TRACKING SOFTWARE
      • 5.2.5.1 ON-PREMISE
      • 5.2.5.2 CLOUD BASED
    • 5.2.6 CLINICAL TRIAL MANAGEMENT SOLUTION
      • 5.2.6.1 ON-PREMISE
      • 5.2.6.2 CLOUD BASED
    • 5.2.7 REGULATORY CONTENT AND INFORMATION MANAGEMENT SOFTWARE
      • 5.2.7.1 ON-PREMISE
      • 5.2.7.2 CLOUD BASED
    • 5.2.8 MEDICAL AFFAIRS SOFTWARE
      • 5.2.8.1 ON-PREMISE
      • 5.2.8.2 CLOUD BASED
    • 5.2.9 OTHERS
      • 5.2.9.1 ON-PREMISE
      • 5.2.9.2 CLOUD BASED
  • 5.3 SERVICES
    • 5.3.1 CLINICAL DATA MANAGEMENT
      • 5.3.1.1 DATA ENTRY AND CASE PROCESSING
      • 5.3.1.2 CLINICAL TRIAL MONITORING
      • 5.3.1.3 CLINICAL TRIAL SAFETY SUBMISSIONS
      • 5.3.1.4 CASE PROCESSING (SAES)
      • 5.3.1.5 OTHERS
    • 5.3.2 DRUG SAFETY SOLUTIONS
      • 5.3.2.1 QUALITY AND MEDICAL REVIEW
      • 5.3.2.2 LITERATURE AND SOCIAL MEDIA MONITORING
      • 5.3.2.3 SAFETY DATABASE
      • 5.3.2.4 INDIVIDUAL CASE STUDY REPORT
      • 5.3.2.5 PERIODIC REPORTS
      • 5.3.2.6 MEDICAL LITERATURE SEARCH
      • 5.3.2.7 SIGNAL DETECTION
      • 5.3.2.8 EXPEDITED REPORTS
      • 5.3.2.9 OTHERS
    • 5.3.3 AGGREGATE SAFETY REPORTING
    • 5.3.4 REGULATORY SERVICES
      • 5.3.4.1 SAFETY REGULATORY SUBMISSIONS
      • 5.3.4.2 POST-MARKETING SURVEILLANCE
      • 5.3.4.3 MEDICAL DEVICE VIGILANCE
      • 5.3.4.4 REGULATORY CONSULTING
      • 5.3.4.5 OTHERS
    • 5.3.5 RISK MANAGEMENT SERVICES
    • 5.3.6 MEDICAL INFORMATION CALL CENTER SERVICES
    • 5.3.7 AUDIT SERVICES
    • 5.3.8 TRAINING SUPPORT SERVICES
    • 5.3.9 OTHERS

6 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET,

BY END USERS 111

  • 6.1 OVERVIEW
  • 6.2 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES
  • 6.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 6.4 HOSPITALS
  • 6.5 KPOS/BPOS
  • 6.6 HEALTHCARE PROVIDERS
  • 6.7 OTHERS

7 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET,

BY DISTRIBUTION CHANNEL 118

  • 7.1 OVERVIEW
  • 7.2 DIRECT SALES
  • 7.3 RETAIL SALES

8 DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY GEOGRAPHY

9 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET,

BY GEOGRAPHY 123

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 U.S.
    • 9.2.2 CANADA
    • 9.2.3 MEXICO
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 UNITED KINGDOM
    • 9.3.3 ITALY
    • 9.3.4 FRANCE
    • 9.3.5 SPAIN
    • 9.3.6 RUSSIA
    • 9.3.7 NETHERLANDS
    • 9.3.8 SWITZERLAND
    • 9.3.9 BELGIUM
    • 9.3.10 TURKEY
    • 9.3.11 AUSTRIA
    • 9.3.12 IRELAND
    • 9.3.13 NORWAY
    • 9.3.14 HUNGARY
    • 9.3.15 POLAND
    • 9.3.16 LITHUANIA
    • 9.3.17 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 JAPAN
    • 9.4.3 SOUTH KOREA
    • 9.4.4 INDIA
    • 9.4.5 AUSTRALIA
    • 9.4.6 SINGAPORE
    • 9.4.7 THAILAND
    • 9.4.8 MALAYSIA
    • 9.4.9 INDONESIA
    • 9.4.10 PHILIPPINES
    • 9.4.11 VIETNAM
    • 9.4.12 REST OF ASIA-PACIFIC
  • 9.5 SOUTH AMERICA
    • 9.5.1 BRAZIL
    • 9.5.2 ARGENTINA
    • 9.5.3 PERU
    • 9.5.4 REST OF SOUTH AMERICA
  • 9.6 MIDDLE EAST AND AFRICA
    • 9.6.1 UAE
    • 9.6.2 SAUDI ARABIA
    • 9.6.3 KUWAIT
    • 9.6.4 SOUTH AFRICA
    • 9.6.5 REST OF MIDDLE EAST AND AFRICA

10 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, COMPANY LANDSCAPE

  • 10.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 10.3 COMPANY SHARE ANALYSIS: EUROPE
  • 10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

11 COMPANY PROFILE

  • 11.1 SYNEOS HEALTH
    • 11.1.1 COMPANY SNAPSHOT
    • 11.1.2 REVENUE ANALYSIS
    • 11.1.3 COMPANY SHARE ANALYSIS
    • 11.1.4 SOLUTION PORTFOLIO
    • 11.1.5 RECENT DEVELOPMENT
  • 11.2 COVANCE INC. (A SUBSIDIARY OF LABCORP)
    • 11.2.1 COMPANY SNAPSHOT
    • 11.2.2 REVENUE ANALYSIS
    • 11.2.3 COMPANY SHARE ANALYSIS
    • 11.2.4 SERVICE PORTFOLIO
    • 11.2.5 RECENT DEVELOPMENTS
  • 11.3 COGNIZANT
    • 11.3.1 COMPANY SNAPSHOT
    • 11.3.2 REVENUE ANALYSIS
    • 11.3.3 COMPANY SHARE ANALYSIS
    • 11.3.4 SOLUTION PORTFOLIO
    • 11.3.5 RECENT DEVELOPMENT

  • 11.4 ACCENTURE
    • 11.4.1 COMPANY SNAPSHOT
    • 11.4.2 REVENUE ANALYSIS
    • 11.4.3 COMPANY SHARE ANALYSIS
    • 11.4.4 SERVICE PORTFOLIO
    • 11.4.5 RECENT DEVELOPMENTS
  • 11.5 PAREXEL INTERNATIONAL CORPORATION
    • 11.5.1 COMPANY SNAPSHOT
    • 11.5.2 PRODUCT PORTFOLIO
    • 11.5.3 RECENT DEVELOPMENTS
  • 11.6 ORACLE
    • 11.6.1 COMPANY SNAPSHOT
    • 11.6.2 REVENUE ANALYSIS
    • 11.6.3 SOLUTION PORTFOLIO
    • 11.6.4 RECENT DEVELOPMENT
  • 11.7 AB CUBE
    • 11.7.1 COMPANY SNAPSHOT
    • 11.7.2 SOLUTION PORTFOLIO
    • 11.7.3 RECENT DEVELOPMENT
  • 11.8 ARISGLOBAL
    • 11.8.1 COMPANY SNAPSHOT
    • 11.8.2 PRODUCT PORTFOLIO
    • 11.8.3 RECENT DEVELOPMENTS
  • 11.9 BIOCLINICA
    • 11.9.1 COMPANY SNAPSHOT
    • 11.9.2 SERVICE PORTFOLIO
    • 11.9.3 RECENT DEVELOPMENTS
  • 11.10 C3I
    • 11.10.1 COMPANY SNAPSHOT
    • 11.10.2 REVENUE ANALYSIS
    • 11.10.3 SERVICE PORTFOLIO
    • 11.10.4 RECENT DEVELOPMENTS
  • 11.11 DRUG SAFETY SOLUTIONS LIMITED
    • 11.11.1 COMPANY SNAPSHOT
    • 11.11.2 SERVICE PORTFOLIO
    • 11.11.3 RECENT DEVELOPMENT
  • 11.12 ENNOV
    • 11.12.1 COMPANY SNAPSHOT
    • 11.12.2 PRODUCT PORTFOLIO
    • 11.12.3 RECENT DEVELOPMENTS
  • 11.13 ERGOMED PLC
    • 11.13.1 COMPANY SNAPSHOT
    • 11.13.2 REVENUE ANALYSIS
    • 11.13.3 SERVICE PORTFOLIO
    • 11.13.4 RECENT DEVELOPMENTS
  • 11.14 GENPACT
    • 11.14.1 COMPANY SNAPSHOT
    • 11.14.2 REVENUE ANALYSIS
    • 11.14.3 PRODUCT PORTFOLIO
    • 11.14.4 RECENT DEVELOPMENTS
  • 11.15 ICON PLC
    • 11.15.1 COMPANY SNAPSHOT
    • 11.15.2 REVENUE ANALYSIS
    • 11.15.3 SERVICE PORTFOLIO
    • 11.15.4 RECENT DEVELOPMENTS
  • 11.16 IQVIA
    • 11.16.1 COMPANY SNAPSHOT
    • 11.16.2 REVENUE ANALYSIS
    • 11.16.3 SOLUTION PORTFOLIO
    • 11.16.4 RECENT DEVELOPMENTS
  • 11.17 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC.
    • 11.17.1 COMPANY SNAPSHOT
    • 11.17.2 SERVICE PORTFOLIO
    • 11.17.3 RECENT DEVELOPMENTS
  • 11.18 PHARMACEUTICAL RESEARCH ASSOCIATES INC.
    • 11.18.1 COMPANY SNAPSHOT
    • 11.18.2 REVENUE ANALYSIS
    • 11.18.3 SOLUTION PORTFOLIO
    • 11.18.4 RECENT DEVELOPMENTS
  • 11.19 UNITED BIOSOURCE LLC
    • 11.19.1 COMPANY SNAPSHOT
    • 11.19.2 SERVICE PORTFOLIO
    • 11.19.3 RECENT DEVELOPMENT

  • 11.20 WORLDWIDE CLINICAL TRIALS
    • 11.20.1 COMPANY SNAPSHOT
    • 11.20.2 SERVICE PORTFOLIO
    • 11.20.3 RECENT DEVELOPMENTS

12 QUESTIONNAIRE

13 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SEGMENTATION 59
  • FIGURE 2 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: DATA TRIANGULATION 62
  • FIGURE 3 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: DROC ANALYSIS 63
  • FIGURE 4 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 64
  • FIGURE 5 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET : COMPANY RESEARCH ANALYSIS 64
  • FIGURE 6 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: INTERVIEW DEMOGRAPHICS 66
  • FIGURE 7 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: DBMR MARKET POSITION GRID 67
  • FIGURE 8 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: VENDOR SHARE ANALYSIS 68
  • FIGURE 9 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET 71
  • FIGURE 10 CLINICAL TRIAL CONDUCTED PER YEAR (AS OF 22 OCTOBER, 2019) 73
  • FIGURE 11 THE MARKET GROWTH IN CLINICAL CONTRACT RESEARCH ORGANISATION (CRO) (IN USD MILLIONS) 74
  • FIGURE 12 THE FUNCTION OF CRO 76
  • FIGURE 13 WORLDWIDE BIOPHARMA COMPANIES R&D EXPENDITURE (IN MILLION U.S. DOLLARS) 78
  • FIGURE 14 RATE OF ORIGIN OF ADE, 28 STATES, 2010 AND 2014 (PER 10,000 STAY) 80
  • FIGURE 15 CURRENT BASIC FEES FOR MARKETING AUTHORISATIONS 81
  • FIGURE 16 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SEGMENTATION 89
  • FIGURE 17 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026 90
  • FIGURE 18 INCREASE IN NUMBER OF ADVERSE DRUG REACTIONS IS DRIVING THE GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET IN THE FORECAST PERIOD OF 2019 TO 2026 91
  • FIGURE 19 SOFTWARE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET IN 2019 & 2026 91
  • FIGURE 20 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE IN THE FORECAST PERIOD OF 2019 TO 2026 92
  • FIGURE 21 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY TYPE (2018) 94
  • FIGURE 22 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY TYPE, 2017-2026 (USD MILLION) 94
  • FIGURE 23 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY TYPE, CAGR (2019-2026) 95
  • FIGURE 24 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY TYPE, LIFELINE CURVE 95
  • FIGURE 25 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY END USER (2018) 112
  • FIGURE 26 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY END USER, 2017-2026 (USD MILLION) 112
  • FIGURE 27 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY END USER, CAGR (2019-2026) 113
  • FIGURE 28 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY END USER, LIFELINE CURVE 113
  • FIGURE 29 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY DISTRIBUTION CHANNEL (2018) 119
  • FIGURE 30 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) 119
  • FIGURE 31 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY DISTRIBUTION CHANNEL, CAGR (2019-2026) 120
  • FIGURE 32 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY DISTRIBUTION CHANNEL, LIFELINE CURVE 120
  • FIGURE 33 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SNAPSHOT (2018) 124
  • FIGURE 34 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018) 125
  • FIGURE 35 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2019 & 2026) 125
  • FIGURE 36 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018 & 2026) 126
  • FIGURE 37 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY TYPE (2019-2026) 126
  • FIGURE 38 NORTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SNAPSHOT (2018) 128
  • FIGURE 39 NORTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018) 129
  • FIGURE 40 NORTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2019 & 2026) 129
  • FIGURE 41 NORTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018 & 2026) 130
  • FIGURE 42 NORTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY TYPE (2019-2026) 130
  • FIGURE 43 EUROPE DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SNAPSHOT (2018) 155
  • FIGURE 44 EUROPE DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018) 156
  • FIGURE 45 EUROPE DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2019 & 2026) 156
  • FIGURE 46 EUROPE DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018 & 2026) 157
  • FIGURE 47 EUROPE DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY TYPE (2019-2026) 157
  • FIGURE 48 ASIA-PACIFIC DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SNAPSHOT (2018) 262
  • FIGURE 49 ASIA-PACIFIC DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018) 263
  • FIGURE 50 ASIA-PACIFIC DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2019 & 2026) 263
  • FIGURE 51 ASIA-PACIFIC DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018 & 2026) 264
  • FIGURE 52 ASIA-PACIFIC DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY TYPE (2019-2026) 264
  • FIGURE 53 SOUTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SNAPSHOT (2018) 338
  • FIGURE 54 SOUTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018) 339
  • FIGURE 55 SOUTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2019 & 2026) 339
  • FIGURE 56 SOUTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018 & 2026) 340
  • FIGURE 57 SOUTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY TYPE (2019-2026) 340
  • FIGURE 58 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: SNAPSHOT (2018) 366
  • FIGURE 59 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018) 367
  • FIGURE 60 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2019 & 2026) 367
  • FIGURE 61 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY COUNTRY (2018 & 2026) 368
  • FIGURE 62 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: BY TYPE (2019-2026) 368
  • FIGURE 63 GLOBAL DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: COMPANY SHARE 2018 (%) 400
  • FIGURE 64 NORTH AMERICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: COMPANY SHARE 2018 (%) 401
  • FIGURE 65 EUROPE DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: COMPANY SHARE 2018 (%) 402
  • FIGURE 66 ASIA-PACIFIC DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET: COMPANY SHARE 2018 (%) 403
Back to Top